keyword
MENU ▼
Read by QxMD icon Read
search

treatment of schizophrenia

keyword
https://www.readbyqxmd.com/read/29793154/juvenile-treatment-with-mglur2-3-agonist-prevents-schizophrenia-like-phenotypes-in-adult-by-acting-through-gsk3%C3%AE
#1
Bo Xing, Genie Han, Min-Juan Wang, Melissa A Snyder, Wen-Jun Gao
Prodromal memory deficits represent an important marker for the development of schizophrenia (SZ), in which glutamatergic hypofunction occurs in the prefrontal cortex (PFC). The mGluR2/3 agonist LY379268 (LY37) attenuates excitatory N-methyl-D-aspartate receptor (NMDAR)-induced neurotoxicity, a central pathological characteristic of glutamatergic hypofunction. We therefore hypothesized that early treatment with LY37 would rescue cognitive deficits and confer benefits for SZ-like behaviors in adults. To test this, we assessed whether early intervention with LY37 would improve learning outcomes in the Morris Water Maze for rats prenatally exposed to methylazoxymethanol acetate (MAM), a neurodevelopmental SZ model...
May 14, 2018: Neuropharmacology
https://www.readbyqxmd.com/read/29791666/prevalence-of-polymorphisms-in-the-ankk1-drd2-drd3-genes-and-metabolic-syndrome-in-refractory-schizophrenia
#2
Jeizziani Aparecida Ferreira Pinto, Pedro Henrique Batista de Freitas, Fernanda Daniela Dorneles Nunes, Paulo Afonso Granjeiro, Luciana Lara Dos Santos, Richardson Miranda Machado
OBJECTIVE: to estimate the prevalence of TaqIA, -141C and rs6280 polymorphisms of the ANKK1, DRD2 and DRD3 genes and evaluate their association with the occurrence of metabolic syndrome in patients with refractory schizophrenia. METHOD: cross-sectional study conducted in the Extended Western Region of Minas Gerais, with refractory schizophrenic patients using the antipsychotic clozapine. Sociodemographic, clinical, anthropometric, biochemical and genetic data were collected...
2018: Revista Latino-americana de Enfermagem
https://www.readbyqxmd.com/read/29790360/-current-and-future-pharmacotherapy-of-severe-psychiatric-disorders
#3
Eva Češková
Despite of tremendous development in CNS research, current treatment is suboptimal especially in severe mental disorders. In medicine, there are two main methods of improving the healthcare provided: seeking new treatment procedures and perfecting (optimizing) the existing ones. Optimization of treatment includes not only practical tools such as therapeutic drug monitoring, but also implementation of general trends into the clinical practice. New pharmacological options include drugs aimed at other than monoaminergic systems and old drugs used before the psychopharmacological era...
2018: Casopís Lékar̆ů C̆eských
https://www.readbyqxmd.com/read/29789034/pharmacological-properties-of-cannabidiol-in-the-treatment-of-psychiatric-disorders-a-critical-overview
#4
G M Mandolini, M Lazzaretti, A Pigoni, L Oldani, G Delvecchio, P Brambilla
Cannabidiol (CBD) represents a new promising drug due to a wide spectrum of pharmacological actions. In order to relate CBD clinical efficacy to its pharmacological mechanisms of action, we performed a bibliographic search on PUBMED about all clinical studies investigating the use of CBD as a treatment of psychiatric symptoms. Findings to date suggest that (a) CBD may exert antipsychotic effects in schizophrenia mainly through facilitation of endocannabinoid signalling and cannabinoid receptor type 1 antagonism; (b) CBD administration may exhibit acute anxiolytic effects in patients with generalised social anxiety disorder through modification of cerebral blood flow in specific brain sites and serotonin 1A receptor agonism; (c) CBD may reduce withdrawal symptoms and cannabis/tobacco dependence through modulation of endocannabinoid, serotoninergic and glutamatergic systems; (d) the preclinical pro-cognitive effects of CBD still lack significant results in psychiatric disorders...
May 23, 2018: Epidemiology and Psychiatric Sciences
https://www.readbyqxmd.com/read/29787962/long-term-outcomes-of-acute-and-transient-psychotic-disorders-the-missed-opportunity-of-preventive-interventions
#5
Grazia Rutigliano, Sergio Merlino, Amedeo Minichino, Rashmi Patel, Cathy Davies, Dominic Oliver, Andrea De Micheli, Philip McGuire, Paolo Fusar-Poli
BACKGROUND: Acute and transient psychotic disorders (ATPD) are characterized by an acute onset and a remitting course, and overlap with subgroups of the clinical high-risk state for psychosis. The long-term course and outcomes of ATPD are not completely clear. METHODS: Electronic health record-based retrospective cohort study, including all patients who received a first index diagnosis of ATPD (F23, ICD-10) within the South London and Maudsley (SLaM) National Health Service Trust, between 1 st April 2006 and 15th June 2017...
May 19, 2018: European Psychiatry: the Journal of the Association of European Psychiatrists
https://www.readbyqxmd.com/read/29787953/public-perceptions-toward-mental-illness-in-japan
#6
Mami Kasahara-Kiritani, Tomoko Matoba, Saeko Kikuzawa, Junko Sakano, Katsumi Sugiyama, Chikako Yamaki, Mieko Mochizuki, Yoshihiko Yamazaki
AIM: The purpose was to characterize public perceptions in Japan of mental illness and how they related to stigma-related attitudes for the same. METHODS: Data were obtained using a vignette survey conducted as a part of the Stigma in Global Context - Mental Health Study and contained a nationally representative sample (n = 994). The survey was conducted using a multi-mode approach (face-to-face interviews, the drop-off-and-pick-up, postal collection) from September to December 2006, with a multi-stage probability sample of Japanese residents aged 18-64 years...
May 16, 2018: Asian Journal of Psychiatry
https://www.readbyqxmd.com/read/29785841/effects-of-antipsychotic-drugs-on-neurites-relevant-to-schizophrenia-treatment
#7
REVIEW
Xu-Feng Huang, Xueqin Song
Although antipsychotic drugs are mainly used for treating schizophrenia, they are widely used for treating various psychiatric diseases in adults, the elderly, adolescents and even children. Today, about 1.2% of the worldwide population suffers from psychosis and related disorders, which translates to about 7.5 million subjects potentially targeted by antipsychotic drugs. Neurites project from the cell body of neurons and connect neurons to each other to form neural networks. Deficits in neurite outgrowth and integrity are implicated in psychiatric diseases including schizophrenia...
May 22, 2018: Medicinal Research Reviews
https://www.readbyqxmd.com/read/29785555/folic-acid-methylfolate-for-the-treatment-of-psychopathology-in-schizophrenia-a-systematic-review-and-meta-analysis
#8
Kenji Sakuma, Shinji Matsunaga, Ikuo Nomura, Makoto Okuya, Taro Kishi, Nakao Iwata
RATIONALE: This study aims to examine whether folate/folic acid/methylfolate/folinic acid supplemented to antipsychotics (FA + AP) is beneficial in schizophrenia treatment. OBJECTIVE: We conducted a comprehensive systematic review and meta-analysis of double-blind, placebo-controlled, randomized clinical trials (RCTs) of FA + AP for schizophrenia. METHODS: The primary outcome was an improvement in total symptoms. Other outcomes were psychopathology subscales (positive, negative, general, and depressive symptoms), discontinuation due to all-cause and adverse events, and individual adverse events...
May 22, 2018: Psychopharmacology
https://www.readbyqxmd.com/read/29783875/need-for-information-in-a-representative-sample-of-outpatients-with-schizophrenia-disorders
#9
Mário César Rezende Andrade, Mike Slade, Marina Bandeira, Sara Evans-Lacko, Denise Martin, Sérgio Baxter Andreoli
BACKGROUND: Providing adequate information and involving patients in treatment have become an essential component of mental health care. Despite this, research regarding the extent to which this need has been met in clinical services is still scarce. AIMS: To investigate the need for information about psychiatric condition and treatment among outpatients with schizophrenia disorders and how this need is associated with service use, adjusting for sociodemographic and clinical characteristics...
May 1, 2018: International Journal of Social Psychiatry
https://www.readbyqxmd.com/read/29781897/recovery-from-schizophrenia-the-case-of-mexican-origin-consumers-and-family-caregivers
#10
Maria M Santos, Alex Kopelowicz, Steven R López
This study examined the views about the future of persons with schizophrenia and their caregivers to understand what is at stake in engaging in recovery. The views of 60 Mexican-origin consumer-caregiver dyads were coded by three independent raters using a recovery literature-based coding system of recovery components: social relations, caregiving burden relief, independence, self-responsibility, and empowerment. General recovery expectations were also rated. Interrater reliability, component frequency, and congruence between the consumers and caregivers' expectations were statistically examined...
May 17, 2018: Journal of Nervous and Mental Disease
https://www.readbyqxmd.com/read/29780333/neurological-soft-signs-spontaneous-and-treatment-emergent-extrapyramidal-syndromes-in-black-africans-with-first-episode-schizophrenia
#11
Akin Ojagbemi, Bonga Chiliza, Toyin Bello, Laila Asmal, Oluyomi Esan, Robin Emsley, Oye Gureje
Background: Very little is known about the relationship between spontaneous and treatment-induced motor syndromes in Africans with first episode schizophrenia. Objective: We investigated the association between spontaneous NSS and EPS, with treatment-induced EPS in a homogenous sample of Black Africans with first episode schizophrenia. Methods: We examined Xhosa (South Africa) and Yoruba (Nigeria) patients, using the Neurological Evaluation Scale and extrapyramidal symptoms scale before and at 3 months after exposure to low dose flupenthixol decanoate...
2018: Frontiers in Psychiatry
https://www.readbyqxmd.com/read/29780332/myoclonic-jerks-and-schizophreniform-syndrome-case-report-and-literature-review
#12
Dominique Endres, Dirk-M Altenmüller, Bernd Feige, Simon J Maier, Kathrin Nickel, Sabine Hellwig, Jördis Rausch, Christiane Ziegler, Katharina Domschke, John P Doerr, Karl Egger, Ludger Tebartz van Elst
Background: Schizophreniform syndromes can be divided into primary idiopathic forms as well as different secondary organic subgroups (e.g., paraepileptic, epileptic, immunological, or degenerative). Secondary epileptic explanatory approaches have often been discussed in the past, due to the high rates of electroencephalography (EEG) alterations in patients with schizophrenia. In particular, temporal lobe epilepsy is known to be associated with schizophreniform symptoms in well-described constellations. In the literature, juvenile myoclonic epilepsy has been linked to emotionally unstable personality traits, depression, anxiety, and executive dysfunction; however, the association with schizophrenia is largely unclear...
2018: Frontiers in Psychiatry
https://www.readbyqxmd.com/read/29780303/closed-loop-deep-brain-stimulation-for-ptsd-addiction-and-disorders-of-affective-facial-interpretation-review-and-discussion-of-potential-biomarkers-and-stimulation-paradigms
#13
REVIEW
Robert W Bina, Jean-Phillipe Langevin
The treatment of psychiatric diseases with Deep Brain Stimulation (DBS) is becoming more of a reality as studies proliferate the indications and targets for therapies. Opinions on the initial failures of DBS trials for some psychiatric diseases point to a certain lack of finesse in using an Open Loop DBS (OLDBS) system in these dynamic, cyclical pathologies. OLDBS delivers monomorphic input into dysfunctional brain circuits with modulation of that input via human interface at discrete time points with no interim modulation or adaptation to the changing circuit dynamics...
2018: Frontiers in Neuroscience
https://www.readbyqxmd.com/read/29779671/resting-state-connectivity-biomarkers-of-cognitive-performance-and-social-function-in-individuals-with-schizophrenia-spectrum-disorder-and-healthy-control-subjects
#14
Joseph D Viviano, Robert W Buchanan, Navona Calarco, James M Gold, George Foussias, Nikhil Bhagwat, Laura Stefanik, Colin Hawco, Pamela DeRosse, Miklos Argyelan, Jessica Turner, Sofia Chavez, Peter Kochunov, Peter Kingsley, Xiangzhi Zhou, Anil K Malhotra, Aristotle N Voineskos
BACKGROUND: Deficits in neurocognition and social cognition are drivers of reduced functioning in schizophrenia spectrum disorders, with potentially shared neurobiological underpinnings. Many studies have sought to identify brain-based biomarkers of these clinical variables using a priori dichotomies (e.g., good vs. poor cognition, deficit vs. nondeficit syndrome). METHODS: We evaluated a fully data-driven approach to do the same by building and validating a brain connectivity-based biomarker of social cognitive and neurocognitive performance in a sample using resting-state and task-based functional magnetic resonance imaging (n = 74 healthy control participants, n = 114 persons with schizophrenia spectrum disorder, 188 total)...
April 13, 2018: Biological Psychiatry
https://www.readbyqxmd.com/read/29779085/progressive-grey-matter-volume-changes-in-patients-with-schizophrenia-over-6-weeks-of-antipsychotic-treatment-and-their-relationship-to-clinical-improvement
#15
Xiao Zhang, Yuyanan Zhang, Jinmin Liao, Sisi Jiang, Jun Yan, Weihua Yue, Dai Zhang, Hao Yan
Cross-sectional and longitudinal studies have identified widespread and progressive grey matter volume (GMV) reductions in schizophrenia, especially in the frontal lobe. In this study, we found a progressive GMV decrease in the rostral medial frontal cortex (rMFC, including the anterior cingulate cortex) in the patient group during a 6-week follow-up of 40 patients with schizophrenia and 31 healthy controls well-matched for age, gender, and education. The higher baseline GMV in the rMFC predicted better improvement in the positive score on the Positive and Negative Syndrome Scale (PANSS), and this might be related to the improved reality-monitoring...
May 19, 2018: Neuroscience Bulletin
https://www.readbyqxmd.com/read/29778806/evaluation-of-antioxidant-potential-of-novel-layered-double-hydroxides-with-caal-and-nial-loaded-with-olanzapine
#16
João Gomes Pontes-Neto, Danilo Augusto Ferreira Fontes, Magaly Andreza Marques de Lyra, Maria Dos Remédios Mendes de Brito, Luíse Lopes Chaves, Pedro José Rolim-Neto, Mônica Felts De La Roca Soares, Lucindo Jose Quintans Júnior, Rivelilson Mendes de Freitas, José Lamartine Soares-Sobrinho
Olanzapine (OLZ), Class II in the Biopharmaceutical Classification System, has low aqueous solubility, hindering its absorption after administration. It is used in the bipolar disorder and schizophrenia treatment, diseases that present the oxidative stress in their pathophysiology. In the search for new Drug Delivery Systems (DDS) that enhance the OLZ dissolution rate, it is also necessary to investigate its antioxidant potential for better understanding. Thus, this study aimed to evaluate the in vitro antioxidant potential of new olanzapine DDS based on two different types of Layered Double Hydroxides (LDH systems)...
May 17, 2018: Life Sciences
https://www.readbyqxmd.com/read/29777584/neuropsychiatric-expression-and-catatonia-in-22q11-2-deletion-syndrome-an-overview-and-case-series
#17
Nancy J Butcher, Erik Boot, Anthony E Lang, Danielle Andrade, Jacob Vorstman, Donna McDonald-McGinn, Anne S Bassett
Individuals with 22q11.2 deletion syndrome (22q11.2DS) are at elevated risk of developing treatable psychiatric and neurological disorders, including anxiety disorders, schizophrenia, seizures, and movement disorders, often beginning in adolescence or early to mid-adulthood. Here, we provide an overview of neuropsychiatric features associated with 22q11.2DS in adulthood. Results of a new case series of 13 individuals with 22q11.2DS and catatonic features together with 5 previously reported cases support a potential association of this serious psychomotor phenotype with the 22q11...
May 19, 2018: American Journal of Medical Genetics. Part A
https://www.readbyqxmd.com/read/29777563/cognitive-and-functional-deficits-in-bipolar-disorder-and-schizophrenia-as-a-function-of-the-presence-and-history-of-psychosis
#18
Christopher R Bowie, Michael W Best, Colin Depp, Brent T Mausbach, Thomas L Patterson, Ann E Pulver, Philip D Harvey
OBJECTIVES: Schizophrenia and bipolar disorder overlap considerably. Schizophrenia is a primary psychotic disorder, whereas approximately half of people with bipolar disorder will experience psychosis. In this study, we examined the extent to which cognitive and functional impairments are related to the presence and history of psychosis across the two disorders. METHOD: A total of 633 participants with bipolar disorder I, schizophrenia, and schizoaffective disorder were recruited for a study on the genetics of cognition and functioning in bipolar disorder and schizophrenia...
May 18, 2018: Bipolar Disorders
https://www.readbyqxmd.com/read/29774635/safety-and-efficacy-from-a-6-week-double-blind-study-and-a-52-week-open-label-extension-of-aripiprazole-in-adolescents-with-schizophrenia-in-japan
#19
Hideo Matsumoto, Jun Ishigooka, Hiroaki Ono, Yoshihiro Tadori
AIMS: The purpose of this study was to evaluate the safety and efficacy of aripiprazole in adolescents with schizophrenia in Japan. METHODS: In a 6-week, randomized, double-blind, dose-comparison study, adolescents (aged 13-17 years) with schizophrenia were randomized to receive aripiprazole 2, 6-12, or 24-30 mg/day. Patients who completed the 6-week study participated in a 52-week, flexible-dose, open-label extension (OLE) study of aripiprazole (initial dose: 2 mg/day, maintenance dose: 6-24 mg/day, maximum dose: 30 mg/day)...
May 18, 2018: Psychiatry and Clinical Neurosciences
https://www.readbyqxmd.com/read/29774628/efficacy-and-safety-of-brexpiprazole-for-the-treatment-of-acute-schizophrenia-in-japan-a-6-week-randomized-double-blind-placebo-controlled-study
#20
Jun Ishigooka, Shuichi Iwashita, Yoshihiro Tadori
AIMS: This study aimed to evaluate the efficacy, safety, and tolerability of brexpiprazole compared to placebo in Japanese patients with acute schizophrenia. METHODS: We conducted a 6-week, multicenter, double-blind, placebo-controlled, phase 2/3 study in Japan. Patients with acute schizophrenia were randomized (1:1:1:1) to receive brexpiprazole 1, 2, or 4 mg or placebo once a day. The primary endpoint was the change from baseline to week 6 in Positive and Negative Syndrome Scale (PANSS) total scores...
May 18, 2018: Psychiatry and Clinical Neurosciences
keyword
keyword
50210
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"